Osteoarthritis Report



PATIENT NAME: Lola Flores VETERINARIAN: MRN: 1073593 SPECIMEN ID: 171686 DRAW DATE: 4-Nov-22 FACILITY: RECEIVED DATE: 9-Nov-22 SPECIES: Canine REPORT DATE: 10-Nov-22 GENDER: Female Spayed

PH: AGE: 15.0 SAMPLE TYPE: Frozen Serum WEIGHT: 7.1 lb PATIENT STAGE: unknown FAX:


BREED: Chihuahua TREATMENT: unknown

Osteoarthritis Panel

Relevant Context (provided on TRF)


 Corticosteroids	Antibiotic	Suspected Mass	Hypercalcemia
 NSAIDs	Anemia	Enlarged Node	B12 Deficiency
Chemotherapy	GI Signs	Fever	Known Disease

HA











Mild Inflam (m): 4 - 9.9 Mod Inflam (M): 10 - 39.9 High Inflam (H): ≥ 40



Intrepretative Comment

Patient values for HA are elevated consistent with degenerative joint disease (OA, IVDD). While CRP is typically elevated in OA with advanced disease, patients being treated with NSAIDS or corticosteriods may have normal levels of inflammation. HA may be elevated in wounds, ACL/CCL injury, severe liver disease, and in patients being treated with PSGAG (ie, Adequan).



Additional Reviewer Comments - need consult? email consult@vdilab.com

code 31662

All comments are general in nature and in absence of detailed knowledge of patient status or treatment. For case-specific consultations, please contact VDI.

Reviewer: RR

Hyaluronic Acid Report



PATIENT NAME: Lola Flores MRN: 1073593 VETERINARIAN: SPECIMEN ID: 171686 DRAW DATE: 4-Nov-22 FACILITY:

 SPECIES:
 Canine
 RECEIVED DATE:
 9-Nov-22

 GENDER:
 Female Spayed
 REPORT DATE:
 10-Nov-22

 AGE:
 15.0
 SAMPLE TYPE:
 Frozen Ser

AGE: 15.0 SAMPLE TYPE: Frozen Serum PH: WEIGHT: 7.1 lb FAX: BREED: Chihuahua

Hyaluronic Acid (ng/mL)

Positive 38.1

Normal: ≤20 Positive: >20

Change from Previous

Patient History

ID	Date	Result n g/mL

Interpretive Comments - need consult? email consult@vdilab.com

Hyaluronic acid is above the reference interval and is indicative of degenerative joint disease, however, severe liver disease can elevate hyaluronic acid. Evaluate liver function. sHA may be elevated in wounds, ACL/CCL injury, severe liver disease, and in patients being treated with PSGAG (ie, Adequan) and oral HA supplement. Supplementing with oral HA has been shown to improve joint function. Follow recommendations below.

Phases of Degenerative Joint Disease					
Pre-/Early Mild		Moderate	Severe		
HA: Serum HA (sHA) below the positive cutoff. HA is being produced and maintained inside the joints.	is being produced but early degeneration allows some HA to	HA: Moderate to high levels of sHA increasing with disease severity. HA is being produced but significant degeneration causes HA to leak into peripheral blood. Joint cushioning & lubrication is negatively affected.	HA: High to declining sHA levels. In severe DJD, chondrocyte cell death limits the production of HA. HA that is produced is leaked into the peripheral blood. Joint cushioning & lubrication is severely affected.		
CRP: Typically absent, except in IMPA	IMPA.	CRP: Mild inflammation may be present in moderate OA,IVDD, due to mechanical damage inside the joint. IMPA presents with elevated CRP.	CRP: Moderate to high inflammation may be present in OA,IVDD. Elevated CRP in IMPA.		
No clinical signs present, but dog may be predisposed or at high risk of DJD.	stiffness or rigidness. Doesn't	Dog may be showing noticeable pain, stiffness, lethargy with dog being uncomfortable, crying, or becoming increasingly reluctant to walk around.	Dog is typically reluctant to walk, go to the bathroom, or perform daily activities due to increased pain that has become unbearable.		

Supplementation Guide

			Dosing Guidelines - Twice Per Day	
PRODUCT NAME	Active Ingredient	PRODUCT STRENGTH	# of Pumps	mL/Day
Trixsyn® Canine Hyaluronan	Sodium Hyaluronate	13mg/pump	1 pump, twice per day	N/A
Trixsyn® Canine Performance	Sodium Hyaluronate Astaxanthin	13mg/pump 1mg/pump	1 pump, twice per day	1 pump, twice per day
Other				